FundaMental Pharma appoints depression drug developer Dr. Hans Eriksson as Chief Medical Officer to advance its lead treatment-resistant depression candidate

Exceptional track record across multiple clinical development programs for depression, three of which have resulted in regulatory ...
Nasdaq

Clearmind Medicine To Develop Novel Intranasal Formulation With Polyrizon

(RTTNews) - Clearmind Medicine Inc. (CMND), Wednesday announced that the company has signed a non-binding Letter of Intent with Polyrizon Ltd. (PLRZ), a development stage biotech company, to develop a ...
Nasdaq

Marvel Biosciences Secures Funding to Develop Child-Friendly Liquid Formulation for Neurodevelopmental Disorders

Calgary, Alberta--(Newsfile Corp. - February 18, 2026) - Marvel Biosciences Corp. (TSXV: MRVL) (OTCQB: MBCOF), is pleased to announce that it is receiving advisory services and funding from the ...
AZ Central

Aspire Biopharma Partners with Microsize to Develop Rapid-delivery Sublingual Powder Formulation of Alprazolam for Faster Anxiety Relief

Collaboration aims to create the first-ever sublingual alprazolam powder, addressing the need for faster-acting anxiety medication. Phase 1 clinical trial of the patent-pending, rapid-onset ...